Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Aspirin-like molecules that inhibit human immunodeficiency virus 1 replication.

Pereira CF, Paridaen JT, Rutten K, Huigen MC, van de Bovenkamp M, Middel J, Beerens N, Berkhout B, Schuurman R, Marnett LJ, Verhoef J, Nottet HS.

Antiviral Res. 2003 May;58(3):253-63.

PMID:
12767473
2.

Spectrum of antiviral activity of o-(acetoxyphenyl)hept-2-ynyl sulphide (APHS).

Pereira CF, Rutten K, Stránská R, Huigen MC, Aerts PC, de Groot RJ, Egberink HF, Schuurman R, Nottet HS.

Int J Antimicrob Agents. 2005 May;25(5):419-26.

PMID:
15848298
3.

APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro.

Pereira CF, Paridaen JT, van de Bovenkamp M, Middel J, Verhoef J, Nottet HS.

J Antimicrob Chemother. 2003 May;51(5):1181-9. Epub 2003 Mar 28.

PMID:
12668583
4.

Aspirin-like molecules that covalently inactivate cyclooxygenase-2.

Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Seibert K, Marnett LJ.

Science. 1998 May 22;280(5367):1268-70.

5.

T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1.

Ojwang JO, Buckheit RW, Pommier Y, Mazumder A, De Vreese K, Esté JA, Reymen D, Pallansch LA, Lackman-Smith C, Wallace TL, et al.

Antimicrob Agents Chemother. 1995 Nov;39(11):2426-35.

7.
10.
11.

Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes.

Aquaro S, Perno CF, Balestra E, Balzarini J, Cenci A, Francesconi M, Panti S, Serra F, Villani N, Caliò R.

J Leukoc Biol. 1997 Jul;62(1):138-43. Review.

PMID:
9226005
12.

Macrophages and lymphocytes differentially modulate the ability of RANTES to inhibit HIV-1 infection.

Gross E, Amella CA, Pompucci L, Franchin G, Sherry B, Schmidtmayerova H.

J Leukoc Biol. 2003 Nov;74(5):781-90. Epub 2003 Jul 15.

PMID:
12960233
13.

Selectively reduced tat mRNA heralds the decline in productive human immunodeficiency virus type 1 infection in monocyte-derived macrophages.

Sonza S, Mutimer HP, O'Brien K, Ellery P, Howard JL, Axelrod JH, Deacon NJ, Crowe SM, Purcell DF.

J Virol. 2002 Dec;76(24):12611-21.

14.

Nitric oxide modulates HIV-1 replication.

Mannick JB, Stamler JS, Teng E, Simpson N, Lawrence J, Jordan J, Finberg RW.

J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):1-9.

PMID:
10534141
15.

In vitro anti-HIV activity of oleanolic acid on infected human mononuclear cells.

Mengoni F, Lichtner M, Battinelli L, Marzi M, Mastroianni CM, Vullo V, Mazzanti G.

Planta Med. 2002 Feb;68(2):111-4.

PMID:
11859458
16.

HIV-1 macrophage tropism is determined at multiple levels of the viral replication cycle.

Fouchier RA, Brouwer M, Kootstra NA, Huisman HG, Schuitemaker H.

J Clin Invest. 1994 Nov;94(5):1806-14.

17.

Inhibition of HIV-1 infection by zinc group metal compounds.

Haraguchi Y, Sakurai H, Hussain S, Anner BM, Hoshino H.

Antiviral Res. 1999 Sep;43(2):123-33.

PMID:
10517314
18.
19.

Efficient synthesis of viral nucleic acids following monocyte infection by HIV-1.

Heinzinger N, Baca-Regen L, Stevenson M, Gendelman HE.

Virology. 1995 Jan 10;206(1):731-5.

20.

Anti-HIV potential of a new interferon, interferon-tau (trophoblastin).

Dereuddre-Bosquet N, Clayette P, Martin M, Mabondzo A, Frétier P, Gras G, Martal J, Dormont D.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Mar 1;11(3):241-6.

PMID:
8603260

Supplemental Content

Support Center